SCHEMBL20856478

SCHEMBL20856478

O=[N+]([O-])c1cc(C(F)F)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 12/20 0.51
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
GRM8 O00222 1/20 0.44
GRM6 O15303 1/20 0.44
GRM4 Q14833 1/20 0.44
TRPV4 Q9HBA0 1/20 0.43
NPBWR1 P48145 1/20 0.43
MCHR1 Q99705 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9886771 0.85 VCAM1 (0.55) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL31387227 0.85 TSHR (0.58) VCAM1MAPTCYP1A2CYP3A4CYP2D6
SCHEMBL1726336 0.82 VCAM1 (0.53) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL9523948 0.82 EPAS1 (0.53) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL16950945 0.82 VCAM1 (0.53) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL257727 0.80 VCAM1 (0.56) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL21064544 0.80 VCAM1 (0.56) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL30155394 0.79 ALDH1A1 (0.58) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL2698568 0.79 ALDH1A1 (0.58) VCAM1MAPTMEN1CYP1A2CYP3A4
SCHEMBL8150935 0.79 PDK1 (0.41) VCAM1MAPTMEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147408-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
US-20210147408-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
WO-2019067702-A9 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL-MYERS SQUIBB COMPANY (US) 2019-04-25 WO disclosed
WO-2019067702-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL-MYERS SQUIBB COMPANY (US) 2019-04-04 WO disclosed
CN-101012174-A Halogenating agents MITSUI CHEMICALS INC (JP) 2007-08-08 CN disclosed
CN-1202086-C Halogenating agents MITSUI CHEMICAL CO LTD (JP) 2005-05-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147408-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 LGALS3, LGALS1, LGALS3BP VCAM1 111/4885MAPT 3108/4885MEN1 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.